Kymera Therapeutics, Inc.·4

Mar 4, 6:00 PM ET

Mainolfi Nello 4

4 · Kymera Therapeutics, Inc. · Filed Mar 4, 2026

Insider Transaction Report

Form 4
Period: 2026-03-02
Mainolfi Nello
DirectorChief Executive Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    [F1]
    2026-03-02+215,000215,000 total
    Exercise: $90.10Exp: 2036-03-01Common Stock (215,000 underlying)
Footnotes (1)
  • [F1]The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact|2026-03-04

Documents

1 file
  • 4
    ownership.xmlPrimary

    4